Full text
Earnings transcript
Read the complete earnings call transcript.
KNSA
Kiniksa Pharmaceuticals, Ltd.
$48.82
0.69
(1.43%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 3.623B |
| Shares Outstanding: | 32.467M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Sanj K. Patel | |||||
| Full Time Employees: | 315 | |||||
| Address: |
| |||||
| Website: | https://www.kiniksa.com |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 270,259 | 423,239 | 677,564 |
| Gross Profit | 213,735 | 362,329 | 370,150 |
| EBITDA | -22,855 | -43,921 | 90,422 |
| Operating Income | -25,196 | -45,616 | 77,221 |
| Net Income | 14,084 | -43,193 | 59,005 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 526,322 | 580,553 | 763,633 |
| Total Liabilities | 87,483 | 142,117 | 196,027 |
| Total Stockholders Equity | 438,839 | 438,436 | 567,606 |
| Total Debt | 12,258 | 9,855 | 9,497 |
| Cash and Cash Equivalents | 107,954 | 183,581 | 165,596 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 13,301 | 25,689 | 25,689 |
| Capital Expenditure | -130 | -277 | -277 |
| Free Cash Flow | 13,171 | 25,412 | 25,412 |
| Net Income | 14,084 | -43,193 | -43,193 |
| Net Change in Cash | -14,761 | 75,627 | 75,627 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,531,980.261 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,615,721.170 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,579,722.850 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -323,012.803 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -306,271.433 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -315,816.068 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 336,320.356 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 360,445.291 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 350,074.554 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,176,644.397 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 1,240,961.983 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 1,213,313.310 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 4.430 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 4.560 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 4.260 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 6 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates KNSA intrinsic value between $5.24 – $13.62 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about KNSA valuation
Is Kiniksa Pharmaceuticals, Ltd. (KNSA) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Kiniksa Pharmaceuticals, Ltd. (KNSA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is KNSA a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether KNSA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is KNSA’s P/E ratio?
You can see KNSA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for KNSA?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is KNSA a good long-term investment?
Whether KNSA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
KNSA
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
1.43
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 18.26 | Year High: | 49.33 | |
| Price Avg 50: | 45.34 | Price Avg 200: | 38.5 | |
| Volume: | 274231 | Average Volume: | 698472 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
